PriceTargets.com logo

NYSE:MYOV - Myovant Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.17
  • Forecasted Upside: 33.08 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$23.42 As of 03/1/2021 11:23 AM ET
▲ +0.96 (4.27%)
1 month | 3 months | 12 months
Get New Myovant Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYOV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYOV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$31.17
▲ +33.08% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Myovant Sciences in the last 3 months. The average price target is $31.17, with a high forecast of $55.00 and a low forecast of $20.00. The average price target represents a 33.08% upside from the last price of $23.42.
Buy
The current consensus among 6 investment analysts is to buy stock in Myovant Sciences. This rating has held steady since May 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2021SVB LeerinkLower Price TargetMarket Perform$28.00 ➝ $26.00Low
i
Rating by A. Fadia at SVB Leerink LLC
1/8/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$30.00 ➝ $28.00High
i
Rating by A. Fadia at SVB Leerink LLC
1/6/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$30.00N/A
i
12/21/2020Robert W. BairdBoost Price TargetOutperform$24.00 ➝ $30.00Medium
i
8/12/2020SVB LeerinkLower Price TargetOutperform$29.00 ➝ $28.00Low
i
7/7/2020SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $29.00High
i
6/23/2020Evercore ISIBoost Price TargetOutperform ➝ Positive$45.00 ➝ $55.00High
i
6/2/2020CitigroupBoost Price TargetNeutral$9.00 ➝ $20.00High
i
Rating by Mohit Bansal at Citigroup Inc.
6/1/2020Evercore ISIBoost Price Target$30.00 ➝ $35.00Medium
i
6/1/2020JPMorgan Chase & Co.Boost Price TargetOverweight$19.00 ➝ $26.00High
i
5/19/2020SVB LeerinkLower Price TargetOutperform$28.00 ➝ $27.00High
i
2/10/2020CowenReiterated RatingBuyHigh
i
Rating by Phil Nadeau at Cowen Inc
2/2/2020CitigroupInitiated CoverageBuy ➝ Neutral$15.00Medium
i
Rating by Mohit Bansal at Citigroup Inc.
11/19/2019JMP SecuritiesReiterated RatingBuy$34.00Low
i
Rating by Jason Butler at JMP Securities
11/19/2019The Goldman Sachs GroupReiterated RatingPositive ➝ Buy$18.00 ➝ $20.00Medium
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
11/12/2019CowenReiterated RatingBuyHigh
i
Rating by Phil Nadeau at Cowen Inc
10/25/2019The Goldman Sachs GroupSet Price TargetBuy$18.00N/A
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
9/6/2019CowenReiterated RatingBuyHigh
i
Rating by Phil Nadeau at Cowen Inc
8/28/2019The Goldman Sachs GroupInitiated CoverageBuy$20.00High
i
8/19/2019SVB LeerinkInitiated CoverageOutperform$26.00High
i
Rating by A. Fadia at SVB Leerink LLC
5/30/2019CitigroupInitiated CoverageBuy$25.00High
i
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
i
2/13/2019BarclaysUpgradeEqual Weight ➝ Overweight$22.00 ➝ $25.00High
i
2/11/2019JMP SecuritiesReiterated RatingBuy$25.00Low
i
11/19/2018CitigroupLower Price TargetBuy ➝ Buy$44.00 ➝ $42.00Medium
i
11/9/2018CowenReiterated RatingBuyHigh
i
10/26/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$25.00Medium
i
Rating by Dana Flanders at The Goldman Sachs Group, Inc.
9/13/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$39.00High
i
4/25/2018CitigroupBoost Price TargetBuy ➝ Buy$17.00 ➝ $44.00Low
i
4/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$18.00High
i
11/14/2017CowenReiterated RatingBuyN/A
i
11/10/2017Robert W. BairdReiterated RatingBuy$20.00N/A
i
10/4/2017JMP SecuritiesReiterated RatingOutperform$23.00 ➝ $25.00Low
i
10/4/2017Robert W. BairdReiterated RatingBuy$20.00Low
i
10/3/2017CowenReiterated RatingBuyLow
i
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ OutperformHigh
i
11/21/2016CowenInitiated CoverageOutperformN/A
i
11/21/2016CitigroupInitiated CoverageBuy$17.00N/A
i
11/21/2016JMP SecuritiesInitiated CoverageOutperform$23.00N/A
i
11/21/2016BarclaysInitiated CoverageOverweight$18.00N/A
i
11/21/2016Robert W. BairdInitiated CoverageOutperform$20.00N/A
i
(Data available from 3/1/2016 forward)
Myovant Sciences logo
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Read More

Today's Range

Now: $23.42
$22.94
$23.55

50 Day Range

MA: $22.40
$20.54
$24.39

52 Week Range

Now: $23.42
$5.98
$30.90

Volume

5,135 shs

Average Volume

1,026,591 shs

Market Capitalization

$2.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Myovant Sciences?

The following Wall Street research analysts have issued stock ratings on Myovant Sciences in the last twelve months: Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Robert W. Baird, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for MYOV.

What is the current price target for Myovant Sciences?

6 Wall Street analysts have set twelve-month price targets for Myovant Sciences in the last year. Their average twelve-month price target is $31.17, suggesting a possible upside of 38.8%. Evercore ISI has the highest price target set, predicting MYOV will reach $55.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $20.00 for Myovant Sciences in the next year.
View the latest price targets for MYOV.

What is the current consensus analyst rating for Myovant Sciences?

Myovant Sciences currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MYOV will outperform the market and that investors should add to their positions of Myovant Sciences.
View the latest ratings for MYOV.

What other companies compete with Myovant Sciences?

Other companies that are similar to Myovant Sciences include ACADIA Pharmaceuticals, United Therapeutics, Ionis Pharmaceuticals, Schrödinger, Sarepta Therapeutics, GW Pharmaceuticals, Evotec, Allakos, Atea Pharmaceuticals, TG Therapeutics, Blueprint Medicines, Turning Point Therapeutics, Perrigo, Maravai LifeSciences and Galapagos.

How do I contact Myovant Sciences' investor relations team?

Myovant Sciences' physical mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company's listed phone number is 44-20-7400-3351 and its investor relations email address is [email protected] The official website for Myovant Sciences is www.myovant.com.